SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) and other VOCs are spreading in Europe. Micro-neutralisation assays with sera obtained after Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in 36 healthcare workers (31 female) demonstrated significant fold change reduction in neutralising titres compared with the original virus: Gamma (P.1) 2.3, Beta (B.1.351) 10.4, Delta 2.1 and 2.6. The reduction of the Alpha (B.1.1.7) variant was not significant. Despite being lower, remaining neutralisation capacity conferred by Comirnaty against Delta and other VOCs is probably protective.
All Keywords
【저자키워드】 COVID-19, variants, B.1.617.2 (Delta), Neutralizing, BNT162b2 vaccination, 【초록키워드】 SARS-CoV-2, Europe, vaccination, VoC, B.1.351, variant, Delta, B.1.617.2, healthcare worker, BNT162b2, B.1.1.7, P.1, sera, female, Gamma, Alpha, Beta, neutralisation, Protective, reduction, not significant, Fold change, titre, SARS-CoV-2 delta, neutralising, demonstrated, reduction in, 【제목키워드】 vaccination, health care workers, Delta, other variant,
【저자키워드】 COVID-19, variants, B.1.617.2 (Delta), Neutralizing, BNT162b2 vaccination, 【초록키워드】 SARS-CoV-2, Europe, vaccination, VoC, B.1.351, variant, Delta, B.1.617.2, healthcare worker, BNT162b2, B.1.1.7, P.1, sera, female, Gamma, Alpha, Beta, neutralisation, Protective, reduction, not significant, Fold change, titre, SARS-CoV-2 delta, neutralising, demonstrated, reduction in, 【제목키워드】 vaccination, health care workers, Delta, other variant,
SARS-CoV-2 Delta(B.1.617.2) 변형 우려(VOC) 및 기타 VOC가 유럽에서 확산되고 있습니다. 36명의 의료 종사자(31명의 여성)를 대상으로 Comirnaty(BNT162b2, BioNTech/Pfizer) 백신 접종 후 얻은 혈청을 사용한 미세 중화 분석은 원래 바이러스와 비교하여 중화 역가에서 상당한 배수 변화 감소를 보여주었습니다. Gamma(P.1) 2.3, Beta(B) .1.351) 10.4, 델타 2.1 및 2.6. 알파(B.1.1.7) 변형의 감소는 중요하지 않았습니다. 더 낮음에도 불구하고 Comirnaty가 Delta 및 기타 VOC에 대해 부여한 잔여 중화 능력은 아마도 보호적일 것입니다.